Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00699491 | Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2018 | clinicaltrials |
| NCT02270372 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | completed | Phase 1 | 22 | Cascadian Therapeutics Inc.INDUSTRY | 1 | May 17, 2018 | clinicaltrials |
| NCT01042535 | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01624441 | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2018 | clinicaltrials |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 112 | Merrimack PharmaceuticalsINDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 4 | Mar 6, 2018 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00998036 | Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | completed | Phase 1 | 9 | Columbia UniversityOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01263145 | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2017 | clinicaltrials |
| NCT02135159 | Patients With Brain Metastases From HER2-positive Breast Cancer(BIRTH) | completed | Phase 1 | 36 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT01104259 | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer | completed | Phase 1 | 50 | University of WashingtonOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00331552 | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT00791037 | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01816035 | Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | University of WashingtonOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00637481 | A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01372644 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial | completed | Phase 1 | 15 | NYU Langone HealthOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00573495 | Multipeptide Vaccine for Advanced Breast Cancer | completed | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01288261 | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 | 14 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT00100750 | Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01238952 | Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | completed | Phase 1 | 4 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01245205 | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2014 | clinicaltrials |
| NCT01077453 | Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer | completed | Phase 1 | 112 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00258349 | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00348699 | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00028535 | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00030615 | Decitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00031278 | Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 12 | PfizerINDUSTRY | 1 | May 30, 2011 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jun 13, 2018source: clinicaltrials